Summit spikes as lead asset undergoes FDA review
Source: SeekingAlpha
2026-01-29 07:47:24 ET
More on Summit Therapeutics
- Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript
- Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- Seeking Alpha’s Quant Rating on Summit Therapeutics
- Historical earnings data for Summit Therapeutics
Read the full article on Seeking Alpha
For further details see:
Summit spikes as lead asset undergoes FDA review
Akeso
NASDAQ: AKESF
AKESF Trading
-2.09% G/L:
$15 Last:
1,400 Volume:
$15.48 Open:
